Denosumab in osteoporosis and oncology

Annals of Pharmacotherapy

Volumn 43, Issue 9, 2009, Pages 1445-1455

  Burkiewicz, Jill S ^a   Scarpace, Sarah L ^b   Bruce, Susan P ^c  

^a MIDWESTERN UNIVERSITY   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

Bone metastases; Breast cancer; Denosumab; Monoclonal antibody; Multiple myeloma; Osteoporosis; Prostate cancer; RANKL; Solid tumor; Tumor necrosis factor

Indexed keywords

ALENDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PLACEBO; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID;

ANEMIA; ARTHRALGIA; ASTHENIA; BACKACHE; BONE DENSITY; BONE METABOLISM; BONE PAIN; BONE TURNOVER; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA EXTRACTION; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FATIGUE; FEVER; FLU LIKE SYNDROME; FRACTURE; GASTRITIS; HUMAN; HYPERPHOSPHATEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOPHOSPHATEMIA; INFECTION; JAW OSTEONECROSIS; LIMB PAIN; METASTASIS; MULTIPLE MYELOMA; NAUSEA; OSTEOARTHRITIS; OSTEOLYSIS; OSTEOPOROSIS; PAIN; PATHOGENESIS; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; SORE THROAT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CONTROLLED CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; MULTIPLE MYELOMA; OSTEOPOROSIS, POSTMENOPAUSAL; PROSTATIC NEOPLASMS; RANK LIGAND;

EID: 69949090458     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M102     Document Type: Review

References (35)

1. Penning-can Beest FJA, Erkens JA, Olson M, Herings RMC. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 2008;19:511-517 DOI 10.1007/s00198-007-0466-1
2. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Clin Proc 2006;81:1013-1022
3. Amgen press release. December 18, 2008. www.amgen.com/media/media-pr- detail.jsp?year=2008&releaseID=1238183 (accessed 15 Feb 2009).
4. Hamdy NAT. Targeting the RANK/RANKL/OPG signaling pathway: a novel approach in the management of osteoporosis. Curr Opin Investig Drugs 2007;8:299-303. (Pubitemid 46557990)
5. Hamdy NAT. Osteoprotegerin as a potential therapy for osteoporosis. Curr Osteoporos Rep 2005;3:121-125 DOI 10.1007/BF02686938
6. Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 2005;5:618-625 DOI 10.1016/j.coph.2005.06.005
7. Dougall WC. RANKL signaling in bone physiology and cancer. Curr Opin Support Palliat Care 2007;1:317-322 DOI 10.1097/SPC.0b013e3282f335be
8. Lewiecki EM. RANK ligand inhibition with denosumab for the management of osteoporosis. Expert Opin Biol Ther 2006;6:1041-1050 DOI 10.1517/14712598.6.10. 1041
9. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004;292:490-495 DOI 10.1001/jama.292.4.490 (Pubitemid 38988958)
10. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-1664 DOI 10.1056/NEJMra030831
11. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176 DOI 10.1016/S0092-8674(00)81569-X (Pubitemid 28180851)
12. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Natl Rev Cancer 2002;2:584-593
13. Bekker PJ. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19:1059-1066 DOI 10.1359/JBMR.040305
14. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor K-B ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastasis from breast cancer. Clin Cancer Res 2006;12:1221-1228 DOI 10.1158/1078-0432.CCR-05-1933 (Pubitemid 43342512)
15. Cremers S, Garnero P. Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease. Potential uses and pitfalls. Drugs 2006;66:2031-2058 DOI 10.2165/00003495- 200666160-00001 (Pubitemid 46372356)
16. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821-831 DOI 10.1056/NEJMoa044459 (Pubitemid 43290920)
17. Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007;22:1832-1841. DOI 10.1359/jbmr.070809
18. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008;43:222-229
19. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008;93:2149-2157 DOI 10.1210/jc.2007-2814 (Pubitemid 351831529)
20. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009;24:153-161 DOI 10.1359/jbmr.0809010
21. Gold DT, Horne R, Borenstein J, Varon S, Macarios D. Preference and satisfaction with a 6-month SC injection versus a weekly tablet for treatment of low bone mass (abstract M372). Presented at: American Society for Bone and Mineral Research 30th Annual Meeting, Montreal, Quebec, Canada, September 13, 2008.
22. Cummings SR, McClung MR, Christiansen C, et al. A phase III study of the effects of denosumab on vertebral, nonvertebral and hip fracture in women with osteoporosis: results from the FREEDOM trial (abstract 1286). Presented at: American Society for Bone and Mineral Research 30th Annual Meeting, Montreal, Quebec, Canada, September 16, 2008.
23. Miller PD. Denosumab: anti-RANKL antibody. Curr Osteoporos Rep 2009;7:18-22. DOI 10.1007/s11914-009-0004-5
24. Lipton A, Steger GG, Figeuroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastasis. J Clin Oncol 2007;25:4431-4437 DOI 10.1200/JCO.2007.11.8604 (Pubitemid 350013849)
25. Lipton A, Steger GG, Figueroa J, et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastasis not receiving prior bisphosphonate treatment. Clin Cancer Res 2008;14:6690-6696 DOI 10.1158/1078-0432.CCR-07-5234
26. Campbell-Baird C, Lipton A, Sarkeshik M, et al. Incidence of acute-phase events following denosumab therapy: results from a randomized, controlled phase II study in patients with breast cancer and bone metastasis (abstract 198). Presented at: 2007 American Society of Clinical Oncology Breast Cancer Symposium, San Francisco, CA, September 7-8, 2007.
27. Gralow J, Lipton A, Fizazi K, Jun S, Yeh H. Effects of denosumab treatment in breast cancer patients with bone metastasis and elevated bone resorption levels after therapy with IV bisphosphonates: results of a phase 2 randomized trial (abstract 1155). Presented at: 2008 San Antonio Breast Cancer Symposium, San Antonio, TX, December 11, 2008.
28. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27:1564-1571 DOI 10.1200/JCO.2008.19.2146
29. Gralow JR, Lipton A, Fizazi K. Effects of denosumab on bone resorption in patients with solid tumors and bone metastasis: comparison of serum-c telopeptide levels from 2 randomized, active-controlled, phase II trials (abstract 9574). J Clin Oncol 2008;26. Presented at: 2008 American Society of Clinical Oncology Annual Meeting, Chicago, IL, May 30-June 3, 2008.
30. Vij R, Horvath N, Spencer A, et al. An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma (abstract 3604). Blood 2007;110. Presented at: The American Society of Hematology Annual Meeting, Atlanta, GA, December 8-11, 2007.
31. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26:4875-4882 DOI 10.1200/JCO.2008.16.3832
32. ClinicalTrials.gov: a service of the National Institutes of Health. www.clinicaltrials.gov/ct2/show/NCT00515463?term=denosumab&rank=5 (accessed 9 Feb 2009).
33. Kendler DL, Benhamou CL, Brown JP, et al. Effects of denosumab vs alendronate on bone mineral density, bone turnover markers, and safety in women previously treated with alendronate (abstract M395). Presented at: American Society for Bone and Mineral Research 30th Annual Meeting, Montreal, Quebec, Canada, September 15, 2008.
34. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 2007;357:1799-1809 DOI 10.1056/NEJMe074941.
35. Gnant M, Mlineritsch B, Schippenger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:679-691 DOI 10.1056/NEJMoa0806285.